The results of our study indicated that bevacizumab in addition to 1st/2nd-generation EGFR-TKIs does not alter the mechanism of acquired resistance in advanced primary EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.